DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,042 filers reported holding DANAHER CORPORATION in Q3 2023. The put-call ratio across all filers is 0.89 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $148,603,961 | +19.5% | 598,968 | +15.6% | 0.62% | +23.5% |
| Q2 2023 | $124,352,880 | +74.9% | 518,137 | +83.7% | 0.51% | +57.1% |
| Q1 2023 | $71,083,596 | +3.5% | 282,033 | +9.0% | 0.32% | -4.7% |
| Q4 2022 | $68,695,739 | +37.0% | 258,819 | +33.3% | 0.34% | +17.0% |
| Q3 2022 | $50,157,000 | +14.0% | 194,190 | +11.9% | 0.29% | +23.5% |
| Q2 2022 | $43,992,000 | -12.0% | 173,524 | +1.8% | 0.23% | -6.4% |
| Q1 2022 | $50,015,000 | -22.9% | 170,509 | -13.5% | 0.25% | -8.1% |
| Q4 2021 | $64,882,000 | +9.8% | 197,204 | +1.6% | 0.27% | +3.4% |
| Q3 2021 | $59,066,000 | +8.0% | 194,016 | -4.8% | 0.26% | +9.6% |
| Q2 2021 | $54,673,000 | +16.4% | 203,731 | -2.4% | 0.24% | +4.8% |
| Q1 2021 | $46,982,000 | +1.8% | 208,734 | +0.5% | 0.23% | -4.6% |
| Q4 2020 | $46,137,000 | +6.0% | 207,693 | +2.7% | 0.24% | -6.6% |
| Q3 2020 | $43,544,000 | +17.9% | 202,219 | -3.1% | 0.26% | +11.7% |
| Q2 2020 | $36,918,000 | +9.6% | 208,777 | -14.2% | 0.23% | -6.9% |
| Q1 2020 | $33,692,000 | -62.6% | 243,420 | -58.5% | 0.25% | -54.7% |
| Q4 2019 | $90,032,000 | +2.6% | 586,605 | -3.4% | 0.54% | -8.4% |
| Q3 2019 | $87,743,000 | -0.6% | 607,510 | -1.6% | 0.60% | -1.8% |
| Q2 2019 | $88,250,000 | -10.6% | 617,476 | -17.4% | 0.61% | -8.5% |
| Q1 2019 | $98,706,000 | +28.5% | 747,662 | +0.4% | 0.66% | +15.5% |
| Q4 2018 | $76,810,000 | -7.8% | 744,865 | -2.8% | 0.57% | +25.4% |
| Q3 2018 | $83,304,000 | +11.1% | 766,646 | +0.9% | 0.46% | +3.2% |
| Q2 2018 | $75,011,000 | -2.5% | 760,139 | -3.2% | 0.44% | -5.7% |
| Q1 2018 | $76,923,000 | +100.1% | 785,649 | +89.7% | 0.47% | +115.6% |
| Q4 2017 | $38,433,000 | +16.0% | 414,064 | +7.2% | 0.22% | +22.5% |
| Q3 2017 | $33,140,000 | +3.6% | 386,335 | +2.0% | 0.18% | -0.6% |
| Q2 2017 | $31,982,000 | +2.5% | 378,935 | +3.8% | 0.18% | 0.0% |
| Q1 2017 | $31,214,000 | +4.1% | 364,905 | -5.2% | 0.18% | 0.0% |
| Q4 2016 | $29,971,000 | +6.5% | 384,738 | +7.2% | 0.18% | +1.7% |
| Q3 2016 | $28,130,000 | -27.5% | 358,841 | -6.6% | 0.18% | -33.8% |
| Q2 2016 | $38,818,000 | +23.1% | 384,335 | +15.6% | 0.27% | +13.7% |
| Q1 2016 | $31,540,000 | +3.9% | 332,490 | +1.7% | 0.23% | +1.7% |
| Q4 2015 | $30,356,000 | +8.8% | 326,827 | -0.1% | 0.23% | -0.4% |
| Q3 2015 | $27,890,000 | -5.0% | 327,311 | -4.6% | 0.23% | +11.1% |
| Q2 2015 | $29,369,000 | +8.1% | 343,135 | +7.2% | 0.21% | +11.8% |
| Q1 2015 | $27,163,000 | +31.0% | 319,945 | +32.2% | 0.19% | +15.5% |
| Q4 2014 | $20,736,000 | +12.7% | 241,934 | -0.1% | 0.16% | +10.3% |
| Q3 2014 | $18,402,000 | -3.6% | 242,198 | -0.1% | 0.15% | 0.0% |
| Q2 2014 | $19,087,000 | +4.7% | 242,438 | -0.3% | 0.15% | -1.4% |
| Q1 2014 | $18,231,000 | +1.4% | 243,078 | +4.4% | 0.15% | -1.3% |
| Q4 2013 | $17,974,000 | +50.9% | 232,818 | +35.5% | 0.15% | +44.2% |
| Q3 2013 | $11,914,000 | +50.5% | 171,873 | +37.4% | 0.10% | +30.0% |
| Q2 2013 | $7,917,000 | – | 125,068 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |